Nona Biosciences

We are honored to announce the appointment of Dr. Di Hong as Chief Executive Officer of Nona Biosciences. Dr. Hong brings over 20 years of leadership experience spanning biopharma, CRO, and investment, with a track record in building innovative ecosystems. His appointment marks a major milestone in Nona’s continued growth and commitment to driving technology innovation, strategic agility, and global collaboration. Join us in welcoming Dr. Hong to the Nona Biosciences team! https://lnkd.in/eZyNQbY2 #NonaBiosciences #Innovation #Biotechnology #Biotherapeutics

It may be Breast Cancer Awareness Month, but awareness should never fade. While progress in treatment has been significant, advanced and resistant breast cancers remain difficult to treat. Nona Biosciences remains hopeful that continued innovation in antibody-drug conjugates (ADCs) will unlock new possibilities for more precise and effective therapies. Explore our latest blog on this evolving field: https://lnkd.in/eEbg4kuZ #BreastCancerAwareness #ADC #Biologics #DrugDevelopment #DrugDiscovery #Oncology #NonaBiosciences

It doesn’t get said or recognized enough so we just want to take a moment to thank and congratulate these giants of modern immunology, Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi, on receiving the 2025 Nobel Prize in Physiology or Medicine for their discoveries in peripheral immune tolerance. Their work laid the foundation for how we understand immune balance and continues to shape therapies for autoimmune disease, cancer, and beyond. Grateful to be part of a field driven by discoveries like these. #NobelPrize #AntibodyDiscovery #Bispecifics #Immunotherapy #NonaBiosciences

💡 The right insights could lead to the next breakthrough Join us at BioJapan on October 8 at 16:10 (JST) for our presentation: "From Idea to IND: Powering the Future of Biotherapeutics with Full-Human Antibody Innovation" where we’ll share how fully human Harbour Mice® platforms, antibody engineering expertise, and bioconjugation capabilities provide the foundation to accelerate the next generation of biotherapeutics. Catch us at 📍 Booth D-99 after the talk to keep the conversation going, whether you're interested in the role of fully human antibodies in next-generation therapeutics or looking for ways to advance your programs. Not attending? Connect with us here: https://lnkd.in/ePDaNDGu #BioJapan2025 #NonaBiosciences #AntibodyDiscovery #HCAb #ADC #Bispecifics #Immunotherapy

Immune cell engagers, ADCs, Next-gen biologics. Whatever your focus, we’re here for you at Oxford Global's Biologics US. Visit us at 📍 Booth 17. From fully human Harbour Mice® platforms to bioconjugation expertise, we provide innovators with the right foundation for next-generation therapies so their programs move forward with confidence. Not attending? Connect with us here: https://lnkd.in/eWm6XWKw #BiologicsUS2025 #ADCdevelopment #AntibodyDiscovery #HCAb #NonaBiosciences

You’ve gotten the insights on VHH antibody Enabled NexGen Therapies. Now it’s time for what’s next - Stop by 📍 Booth 650 It was a lively session, and we thank everyone who joined our plenary on “VHH Antibody Enabled NexGen Therapies: Past, Present and Future.” If you’d like to continue the conversation or didn’t get the chance to connect, our team is right in front at 📍 Booth 650. Whether you’re interested in diving deeper into VHH antibody innovation or exploring how to advance your next program, we’d be glad to keep the discussion going. Not attending? Connect with us here: https://lnkd.in/efNFkFpy #FestivalOfBiologics #NonaBiosciences #HCAb #AntibodyDiscovery #bispecifics #Immunotherapy

Today's keynote presentation at the Festival of Biologics Basel - "VHH Antibody Enabled NexGen Therapies: Past, Present and Future" Be sure to join us today at 9:35 a.m. where we’ll walk through the past, present, and future of VHH and HCAb fragments. From early origins to fully human VH, we’ll show how these formats address stability and immunogenicity challenges while enabling advances in bispecifics, CARs, ADCs, and RNA-based therapies. Not attending? Connect with us here: https://lnkd.in/eGKFWU_C #FestivalOfBiologics #NonaBiosciences #HCAb #AntibodyDiscovery #bispecifics #Immunotherapy

How can form meet function in therapeutic design? We welcome you to join us for a discussion on aligning therapeutic design with biological mechanisms. Be part of the conversation at the Festival of Biologics in Basel on October 1 at 11:45 a.m. during our roundtable session. Not attending? Connect with us here: https://lnkd.in/eVWRS9Zq #FestivalOfBiologics #NonaBiosciences #HCAb #AntibodyDiscovery #bispecifics #Immunotherapy

Next-gen therapeutics begin with the right foundation. Visit us at 📍 Booth 650 during the Festival of Biologics in Basel to see how Nona Biosciences provides that foundation with fully human Harbour Mice® platforms, producing H2L2 and HCAb formats with high developability and no need for humanization. Whether you’re advancing bispecifics, ADCs, CARs, mRNA-based therapeutics, or other modalities, our platform gives you the edge to move programs from discovery into development, with flexible collaboration models adding further support along the way. Not attending? Connect with us here: https://lnkd.in/e9CcyvtF #FestivalOfBiologics #NonaBiosciences #HCAb #AntibodyDiscovery #bispecifics #Immunotherapy

It’s always a privilege to connect with one of our key partners during the CAR-TCR Summit Series. Thank you Mike Fitzpatrick for the thoughtful exchange and continued collaboration. We believe Umoja’s VivoVec™ platform is game-changing for advancing in vivo CAR-T therapies. By bringing together our respective strengths, we aim to simplify treatment, reduce immunogenicity, and expand patient access through: 🐭 Nona’s HCAb Harbour Mice® platform and NonaCARFx™ screening – enabling discovery of fully human, functional CAR binders. 🧬 Umoja’s VivoVec™ gene delivery platform – empowering a patient’s own immune system to generate CAR-T cells directly in vivo. Thank you Umoja Biopharma for leading this important work and for allowing us to partner with you on the journey ahead. #CAR #TCR #CellTherapy #GeneTherapy #NonaBiosciences #UmojaBiopharma #CARTCRSummit